Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023)
Ironwood Pharmaceuticals' (IRWD) quarterly Income from Non-Controlling Interests came in at -$658000.0 in Q4 2023, up 52.01% quarter-over-quarter from -$1.4 million in Q3 2023.
Powered by 
Analysis
Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Ironwood Pharmaceuticals has disclosed Income from Non-Controlling Interests across 2 years of filings, most recently posting -$658000.0 for Q4 2023.
- In Q4 2023, Income from Non-Controlling Interests changed N/A year-over-year to -$658000.0; the TTM figure through Dec 2023 stood at -$29.3 million (changed N/A YoY), while the FY2025 annual figure was $6.4 million, up 2376.36% from the prior year.
- Income from Non-Controlling Interests came in at -$658000.0 for Q4 2023 at Ironwood Pharmaceuticals, up from -$1.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$658000.0 in Q4 2023 to a low of -$27.3 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Ironwood Pharmaceuticals | 674.06 Mn | 594.93 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -658,000.00 |
| Sep 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | -27.29 Mn |
| Sep 30, 2010 | 1.52 Mn |
| Jun 30, 2010 | -73,000.00 |